RU2057534C1 - Method of trophic ulcer treatment - Google Patents

Abstract

FIELD: medicine. SUBSTANCE: preparation is 0.25-1% ointment which contains highly active complex of proteinases "Moricrase" exibiting collagenolytic action on necrotic tissues. Preparation is stable at the room temperature, shows positive effect on the blood system coagulation. The oil "Eiglisol" (ointment base) shows healing action. EFFECT: increased effectiveness of preparation. 2 dwg

Description

 The invention relates to pharmacology and can be used in medicine and veterinary medicine for the treatment of purulent-trophic ulcers, infected wounds and bedsores in humans and animals.

 Known drug Elase (Parke Davis) for the treatment of pressure sores, which is a mixture of the enzymes fibrinolysin and deoxyribonuclease. The disadvantages of the drug include the relatively low proteolytic activity of fibrinolysin and the high cost of the second component of the deoxyribonuclease preparation.

 Known domestic drug "Chemopsin", which in composition and mechanism of action is close to the proposed solution and can be taken as a prototype.

The method has the following disadvantages:
lack of collagenolytic effect on necrotic tissue;
instability in solution;
the absence in the preparation of a component with a healing effect;
lack of information on the effect of the drug on the blood fibrinolysis system for external use.

 The aim of the invention is the creation of an effective drug for the treatment of purulent-trophic ulcers and pressure sores, containing a purified preparation of proteinases "Morikrazu" with high proteolytic and collagenolytic activity, as well as fish oil "Aiglisol".

 The essence of the invention lies in the fact that the preparation for the treatment of purulent-trophic ulcers and pressure sores contains morikrazu and Eiglisol oil in the following composition, morikraz 0.25-1; oil 80; lanolin 4-5; paraffin 12-15.

 Figure 1 shows a nomogram of changes in coagulation and fibrinolysis in rats with ulcers after use, 1% moricrase ointment; in FIG. 2 the same, after applying the ointment base (on the circumference the indicators before treatment are postponed, taken as 100% along the radii of their change in).

In FIG. 1,2 the following notation is given:
1 fibrinogen;
2 recalcification time;
3 indicator of ointment on thromboelastogram;
4 time of lysis of a clot of euglobulins;
5 lysis zones on standard fibrin plates;
6 plasminogen activator;
7 plasmin;
8 anti-activator.

 Moricrase is a purified proteinase preparation with high proteolytic and collagenolytic activity. In addition to trypsin and chymotrypsin, it also contains elastase, carboxypeptidases A and B, which contributes to faster and deeper proteolysis of dead tissue. In addition, unlike animal trypsin and chymotrypsin, similar enzymes of the drug moriracrase have a pronounced collagenolytic effect, which also contributes to the destruction of trophic tissues.

The solution of moricrase maintains proteolytic activity for a long time. Thus, if stored in a refrigerator at 4 ^{° C} the aqueous solution was completely retains activity for three weeks at room temperature for 19 days (35 days the activity is reduced 2-fold) at 37 ^C. The preparation is stable for 10 days. For wound healing, an ointment containing 0.25-1% moricrase is used, in addition to the usual components of lanolin and paraffin, Aiglisol oil.

Rats with spontaneous purulent-ulcerative formations on the neck, the sizes of which ranged from 1x1 to 2 x 1.5 cm ² (these pathological formations contained necrotic tissues, large subcutaneous and external accumulations of pus), were applied with a spatula to the ulcer and nearby tissues. The experiment lasted for 20 days. After 10 days, a gradual tightening of the wound surface was noted in the group of experimental animals. Subsequent use of the drug led to the formation of a more dense skin area than at the first stage and did not prevent the appearance of a hairline in place of a healed wound. As a control, there were rats, which were applied to the wound surface with a base containing fish oil. The wound healing process in animals of this group was slower.

PRI me R 1. Rat 1. On the neck there is a purulent ulcer measuring 2.5 x 1.5 cm ² .

 After 10 days of lubrication, the wound cleansed completely of necrotic masses and pus and became covered with thin pink skin. After 20 days, the skin became denser, but the hairline was absent.

PRI me R 2. Rat 2. On the front of the neck a small ulcer 1 x 1.2 cm ² , festering. After 10 days of lubrication, the wound cleansed and healed, hair began to appear.

 The given examples confirm the therapeutic effect of the drug moricrase.

 The use of the drug allows the treatment of animals for a rather short time. The combination of morigrase with Eiglisol oil allows you to clean the wounds of pathological masses and lead to healing.

Faster healing of wounds occurred when applying an ointment with a moricrase content of 1%
The study of indicators of the blood coagulation system in rats was carried out after a 10-day use of a 1% Moricrase drug. As can be seen from the scheme, the use of a 1% ointment leads to an increase in the concentration of fibrinogen without a noticeable change in blood coagulation over the time of recalcification.

 Similar changes, but expressed to a lesser extent, are revealed with the use of lower doses. An increase in fibrinolytic activity is associated with the activation of plasminogen, which is a positive effect.

Claims (1)

 METHOD FOR TROPHIC ULCER TREATMENT, including application of a protoinase-based preparation to an ulcer and nearby tissues, characterized in that, in order to enhance the proteolytic effect and improve blood coagulation, 0.25 1% Moricrase is used as a protenase, and dead skin is treated tissues are carried out with a composition additionally containing Aiglisol oil.

Images